Skip to content

Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery

Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01805856
Acronym
Ito-RCT1
Enrollment
2164
Registered
2013-03-06
Start date
2010-11-30
Completion date
2012-05-31
Last updated
2013-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parathyroid Disease, Thyroid Disease

Keywords

antimicrobial prophylaxis, AMP, surgical site infection, SSI, thyroid, thyroidectomy, parathyroid, surgery

Brief summary

The effectiveness of antimicrobial prophylaxis (AMP) for prevention of surgical site infection (SSI) following thyroid and parathyroid surgery remains uncertain. Present prospective randomized control study (Ito-RCT1) assessed the effectiveness of AMP in clean neck surgery associated with thyroid and parathyroid disease.

Detailed description

Between November 2010 and April 2012, 2164 consecutive patients who agreed to attend the randomized control study were enrolled. All the participants received surgery for thyroid and parathyroid disease at Ito Hospital and randomized in three groups; Group A (n=541): operation with AMP (PIPC, piperacillin sodium), Group B (n=541): operation with AMP (CEZ, cefazolin sodium), and Group C (n=1082): operation without AMP. Exclusion criteria * Patients who did not agree to attend the randomized control study. * Patients who received the operation including mediastinum with sternotomy. * Patients who received the operation including additional resection of trachea, esophagus and larynx. * Patients who received the re-operation for post-operative bleedings. * Patients who had known allergy to cephem or penicillin.

Interventions

DRUGPIPC piperacillin sodium
DRUGCEZ, cefazolin sodium

Sponsors

Ito Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
10 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Between November 2010 and April 2012, 2164 consecutive patients who agreed to attend the randomized control study were enrolled. All the participants received surgery for thyroid and parathyroid disease at Ito Hospital.

Exclusion criteria

* Patients who did not agree to attend the randomized control study. * Patients who received the operation including mediastinum with sternotomy. * Patients who received the operation including additional resection of trachea, esophagus and larynx. * Patients who received the re-operation for post-operative bleedings. * Patients who had known allergy to cephem or penicillin.

Design outcomes

Primary

MeasureTime frameDescription
Surgical site infections after thyroid and parathyroid surgery1 month after operationSurgical site infection was defined as patients who are necessary to receive the treatment such as surgical drainage or antibiotic medication. When the patients receive the surgical drainage, microbial culture was performed.

Secondary

MeasureTime frameDescription
Side effect of the drug for Antimicrobial prophylaxis4 days after operationThe appearances of drug allergic reactions (skin rash and anaphylactic shock) were checked at operating room. Blood test to check up liver and renal dysfunction was done on the 3rd POD. Liver and renal dysfunction is clinically diagnosed by patients' own physicians and the author, and only counted the cases which function got worse compared to preoperative data.

Other

MeasureTime frameDescription
Urinary tract infection after operation with or without antimicrobial prophylaxis1month after operationIf the patients had a symptom of urinary tract infection, additional blood test and urine test were done to diagnose infection accurately.

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026